June, 2017:
- Inhibiting CFH May Improve Responses to Rituximab in CLL
- Savolitinib Shows Promise for MET-driven Papillary Renal Cell Carcinoma
- Dermatomyositis and Cancer Risk
- Tamoxifen- and Placebo-induced Symptoms Yield Similar Adherence Rates to Breast Cancer Prophylactics
- Adjuvant Anthracycline Does Not Improve DFS in TOP2A-normal Breast Cancer
- Ginger Does Not Improve Chemotherapy-associated Nausea
- Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer
- Restoring ASPP1 May Improve Outcomes in Clear Cell RCC
- Tamoxifen or Exemestane With Ovarian Function Suppression Prolongs Breast Cancer-free Interval
- Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells
- TPX-0005 Granted Orphan Drug Designation for Non-small Cell Lung Cancer
- Palbociclib Plus Fulvestrant Improves PFS Among Premenopausal Patients With Breast Cancer
- Absolute Lymphocyte Counts Predictive of Survival With CLL Post-FCR
- In Focus: Blinatumomab for Non-Hodgkin Lymphoma
- Evofosfamide Not Recommended in First-line Sarcoma Treatment
- Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib
- Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab
- TKI Discontinuation for Patients With CML Could Save Billions
- Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation
- FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers
- MRI Imaging in Adjunct With Mammograms Improves Secondary Breast Cancer Detection
- FDA Approves Dabrafenib and Trametinib for BRAF<sup>V600E</sup>-mutant NSCLC
- First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC
- Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma
- Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma
- Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain
- Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine
- Early Taxane Switching May Improve PSA Response Rates in Prostate Cancer
- Once-daily Radiotherapy Not Superior to Twice-daily in SCLC
- Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach
- Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths
- Potential Drug- and Herb-Drug Interactions Among Patients With Cancer
- Intervention-guided Program Improves Weight Loss Among African American Breast Cancer Survivors
- Dietary Nutrients and Oncogenic HPV Infections
- Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma
- FDA Expands Daratumumab Approval for Multiple Myeloma
- In Focus: Abemaciclib for Advanced Breast Cancer
- PD-L2 Expression May Be Associated With Response to Pembrolizumab in HNSCC
- Phase 2 Trial of Poly-ICLC Vaccination for Solid Tumors
- Phase 2 Trial of GL-0817 With Cyclophosphamide for Squamous Cell Carcinoma of the Oral Cavity
- Future Treatment Modalities in Sarcoma: Insights From ASCO 2017
- OS Milestone Rate May Be Useful Secondary Endpoint in NSCLC Trials
- Phase 2 Trial of SBRT for Patients With Inoperable Head and Neck Cancer
- Study of Shoulder Disability Among Patients With Head and Neck Cancer Post-surgery
- Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer
- HBV Vaccine Can Prevent Non-Hodgkin Lymphoma in Adolescents
- Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer
- Momelotinib vs Ruxolitinib for Patients With Myelofibrosis
- Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck
- Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?
- Palifosfamide With Platinum Doublet Fails To Prolong Survival in SCLC
- Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer
- Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer
- Engagement Is Survival: My Take on ASCO 2017
- Mitigation of Anticancer Drug Wastage Could Save 17% of Costs
- Response-based Therapy Intensification Improves Survival in Adult ALL
- aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer
- Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy
- Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials
- Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN
- Cryosurgery: The Future of Breast Cancer Treatment?
- Burtomab Granted Breakthrough Therapy Designation for Metastatic Neuroblastoma
- FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer
- Prolonged PFS With Brentuximab Vedotin in Cutaneous T Cell Lymphoma
- Intermittent Letrozole May Benefit Some Patients With Breast Cancer
- Pembrolizumab Active in Advanced Gastric Cancer
- Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD
- Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment
- High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer
- Momelotinib for Previously Treated Patients With Myelofibrosis
- Gastric Linitis Plastica Diagnosis Uses Endoscopic and Radiologic Studies Approach
- Dabrafenib Plus Trametinib Promising in Melanoma
- Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer
- Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer
- Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases
- Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
- Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer
- Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2
- TREnd: Adding Palbociclib to Endocrine Therapy Provides Clinical Benefits in Breast Cancer
- MARIANNE Update: T-DM1 Does Not Significantly Improve Survival in HER2+ Breast Cancer
- Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer
- Establishing a Short-term Response Endpoint for mCRPC Trials
- Electronic Patient-reported Outcome System Improves Survival Among Patients With Cancer
- Vemurafenib Active in BRAF<sup>V600</sup>-mutant NSCLC
- Abemaciclib Plus Fulvestrant Is Effective Therapy in Endocrine-resistant Breast Cancer
- PALOMA-1 Update: Survival With Palbociclib Not Significantly Improved in ER+/HER2- Breast Cancer
- Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
- Korean Red Ginseng Improves Cancer-related Fatigue in Colorectal Cancer
- Personalizing Care for Patients With Sarcoma
- Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment
- Promising Activity Reported for Nivolumab in Gynecologic Cancers
- Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer
- Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes
- Buparlisib Plus Fulvestrant Effective But Increases Toxicity in Breast Cancer
- Q&A With Michael A. Dyer, MD: Unraveling the Retinoblastoma Epigenome
- Cervical Cancer Progression More Likely With HIV Infection
- Midtreatment FDG-PET-Driven RT Escalation Promising in NSCLC
- Better Functional Outcomes With Stereotactic Conformal Radiotherapy for Brain Tumors
- CML: Patient Study Links Insurance Status at Diagnosis and Overall Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL
- Bloodroot and Cancer
- Perioperative Gabapentin May Improve Pain Management in Head and Neck Cancer
- ACA Decreased Non-Insurance Rates Among Patients With Head and Neck Cancer
- Acetaminophen May Decrease Opioid Use After Head and Neck Cancer Surgery